Medicine
Sumatriptan 5 mg nasal spray
Sumatriptan 5 mg nasal spray is a generic prescription medicine for nasal use, made by 2 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store between 36°F and 86°F (2°C and 30°C). Protect from light.
Key facts
- Active ingredient (INN)
- Sumatriptan
- Brand
- Sold under the generic name
- Strength
- 5 mg
- Dosage form
- Nasal spray
- Route
- Nasal
- Packs
- 6 containers
- Manufacturers
- Bryant Ranch PrepackPadagis Israel Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store between 36°F and 86°F (2°C and 30°C). Protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N02CC01 Sumatriptan
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 4 October 2020
- Identifiers
- RxCUI 313159, 314227DailyMed set ID 6d521807-e5ce-498d-a224-5534c5ea61fa, c7a5deb9-5de4-4a70-bb87-a40084b46f48NDC 45802-619, 63629-8701Application ANDA213465, ANDA213650
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 6 container in 1 carton / 1 spray in 1 container | 45802-619-06 | Padagis Israel Pharmaceuticals | 4 October 2020 |
| 6 container in 1 carton / 1 spray in 1 container | 63629-8701-1 | Bryant Ranch Prepack | 21 July 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 28 December 1992 | Drugs@FDA |
| EU (EMA) | Refused | EMA medicines data |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Sumatriptan
Clinical summary
Sumatriptan is a serotonin-1b and serotonin-1d receptor agonist indicated in adults for the acute treatment of migraine, with or without aura, and the acute treatment of cluster headache, among other approved uses. MedsAcross supplies Sumatriptan for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SumatriptanFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- IMITREX prescribing information (GlaxoSmithKline) · U.S. National Library of Medicine, DailyMed
Need Sumatriptan 5 mg nasal spray for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.